

TABLE OF CONTENTS

12. Ethics, Patents and Regulatory issues	6
Introduction	6
Ethical concerns about genetic diagnosis	6
Ethical guidelines for molecular diagnostics	7
Ethical aspects of direct-to-consumer genetic services	8
US public attitudes about genetic testing	9
Opinion of European geneticists about DTC genetic testing	9
Genetic testing for susceptibility to adult-onset cancer.....	9
Ethics of preimplantation genetic diagnosis	10
<i>Preimplantation genetic diagnosis to screen for hereditary diseases</i>	10
<i>PGD to test for susceptibility to cancer</i>	10
<i>PGD and stem cells</i>	11
Genetic research on stored tissues	11
Informed consent in clinical trials of in vitro devices	12
Concluding remarks about ethical issues	12
Insurance underwriting and gene tests	12
<i>Should genetic information be available to health insurers?</i>	13
<i>A need for the re-examination of current views</i>	13
<i>Genetic Information Nondiscrimination Act of US</i>	14
<i>Impact of the US health care reform bill on genetic testing issues</i>	14
Patents for molecular diagnostics	14
PCR patents	14
Patenting DNA sequences	14
US policy on gene patenting relevant to molecular diagnostics.....	15
The impact of disease gene patents on molecular diagnostics	16
Licensing problems associated with genetic testing.....	16
BRCA1 and BRCA2 gene patents	16
Role of the WHO in genetic testing standards	17
NIH's Genetic Testing Registry	18
Regulatory issues in the US	18
Assay Migration Studies for In Vitro Diagnostic Devices	18
Assessment of diagnostic accuracy	18
<i>Sensitivity and specificity</i>	19
<i>Documentation of diagnostic accuracy</i>	19
Discovery of incidental findings on genetic screening	20
Evaluation of companion diagnostics/therapeutic for cancer	21
FDA regulation of multivariate index assays	21
FDA guidance for IVDs to detect pathogens	22
FDA guidelines for devices to detect and differentiate HPV	23
FDA's Microarray Quality Control	23
FDA and point-of-care diagnosis	24
Genetic testing of rare disorders	24
Quality control of molecular diagnostic laboratory procedures.....	25
Quality assurance of rna expression profiling	25
Quality control of point-of-care tests	25
Regulation of IVD by the FDA	26
Regulation of in vitro companion diagnostics by the FDA	27
Regulation of in vivo diagnostics by the FDA.....	28
Regulation of laboratory developed tests.....	28
<i>Home-brew tests</i>	28
<i>Laboratory-developed tests used by Medicare recipients</i>	28
<i>Oversight of LDTs by the FDA</i>	29
Regulatory aspects of FISH	30
Regulation of genetic testing	30
<i>Role of the FDA in genetic testing</i>	30
Regulation of direct-to-consumer genetic testing	31
<i>Need for regulatory oversight of DTC</i>	31
Regulatory issues concerning blood and plasma products	33
United States Diagnostics Standards	33
Regulation of in vitro diagnostics in the EU	34
EU regulations for testing of blood products	34
Regulation of genetic testing in EU	34
Evaluation of diagnostic laboratory tests in the UK	35
Pre-implantation genetic diagnosis in the UK	36
13. Markets for Molecular Diagnostics	38
Introduction	38
Methods for study of molecular diagnostic markets	38

The overall market for diagnostic technologies.....	39
Molecular diagnostic markets according to technologies	39
Marketing strategies according to technologies	40
Nucleic acid isolation market	40
Market for PCR-based tests	40
<i>Markets for PCR instrumentation</i>	<i>40</i>
<i>Markets for real-time PCR and qRT-PCR</i>	<i>41</i>
<i>PCR market players.....</i>	<i>41</i>
DNA sequencing market.....	42
Cytogenetic market	42
<i>Market for FISH technologies.....</i>	<i>42</i>
Biochip/microarray market.....	43
Biosensor market.....	43
Nanobiotechnology for molecular diagnostics	43
Markets for gene expression technologies	44
Reagents and other disposable laboratory materials	44
Market for immunochemistry diagnostic.....	44
Markets for tissue diagnostics.....	44
Molecular diagnostic markets according to therapeutic areas.....	44
Genetic disorders	45
Prenatal testing	46
Cancer.....	46
<i>Potential markets for cancer diagnosis according to type of cancer.....</i>	<i>47</i>
Infectious diseases.....	48
<i>Sexually transmitted diseases.....</i>	<i>50</i>
<i>Hospital-acquired infections.....</i>	<i>50</i>
<i>Testing for HIV drug resistance.....</i>	<i>51</i>
<i>Potential markets for avian influenza diagnostics.....</i>	<i>51</i>
Cardiovascular diseases	52
Neurological disorders	52
Food testing	52
Screening of blood for transfusion	53
Tissue typing for transplantation	53
Molecular diagnostic markets relevant to pharmaceutical industry	53
Molecular diagnosis and personalized medicine markets.....	53
Growth of markets relevant to personalized medicine	53
Marketing opportunities according to geographic areas	54
Unmet needs in molecular diagnostics	55
Major market trends	55
Markets according to home-brew and FDA-approved tests	55
Decentralization of molecular diagnostics	56
Point-of-care testing.....	56
Development of personalized medicine	57
<i>Cost of sequencing the human genome.....</i>	<i>57</i>
<i>Cost of genotyping.....</i>	<i>58</i>
<i>Marketing companion diagnostics for personalized medicine</i>	<i>58</i>
Development of low-cost tests.....	59
Simplification of test procedures	59
Increasing role of proteomics in clinical diagnostics	59
Forensic and legal applications.....	60
Marketing strategies	60
Role of alliances in commercialization of molecular diagnostics	60
<i>Acquisitions vs collaborations</i>	<i>61</i>
<i>Analysis of collaborations in molecular diagnostics</i>	<i>64</i>
<i>Licensing of the technologies.....</i>	<i>65</i>
Strategies related to laboratory facilities and technologies	65
Strategies relevant to the healthcare system	65
<i>Cost-Benefit studies</i>	<i>65</i>
<i>Genetic susceptibility testing</i>	<i>66</i>
<i>Preventive medicine strategies</i>	<i>66</i>
<i>Targeting treatable and common diseases.....</i>	<i>66</i>
Information/education	67
<i>Physician education.....</i>	<i>67</i>
<i>Patient education</i>	<i>67</i>
<i>European diagnostic information platform</i>	<i>68</i>
Regulatory strategies	68
Merger of in vitro and in vivo diagnostics	68
Integration of diagnostics with therapeutics	69
Diagnostic applications in clinical trials.....	69
Prospects for development of new technologies	69
Drivers for the development of molecular diagnostics	69

Factors slowing the development of molecular diagnostics	70
Government support of research relevant to molecular diagnostics	71
<i>Cost of sequencing the human genome</i>	71
European projects for improving molecular diagnostics	73
<i>European Consortium for developing new DNA analysis tools</i>	73
<i>EU project for improvement of IVD tools procedures</i>	73
<i>Genetic knowledge parks in the UK</i>	73
Molecular diagnostic opportunities in defense against bioterrorism	74
Molecular diagnostics for food safety	74
POC diagnostics for the developing countries	75

14. Companies involved in molecular diagnostics	76
Introduction	76
Major players in molecular diagnostics	76
Profiles of selected companies	77
Collaborations	462

Tables

Table 13-1: Share of in vitro diagnostics in the global diagnostic market 2011-2021	39
Table 13-2: Molecular diagnostics markets according to technologies from 2011-2021	39
Table 13-3: PCR market 2011-2021	40
Table 13-4: Molecular diagnostics markets according to applications 2011-2021.....	44
Table 13-5: Markets in 2011 for tests to screen healthy persons for genetic disorders	45
Table 13-6: Markets in 2011 for molecular diagnostic tests for cancer	46
Table 13-7: Molecular diagnostic markets for selected cancers 2011-2021	47
Table 13-8: Markets value in 2011 for molecular diagnostic screening for infections.....	49
Table 13-9: Future markets for molecular diagnosis of infections 2012-2016.....	49
Table 13-10: Future markets for HAI diagnostics 2012-2016.....	50
Table 13-11: Growth of markets relevant to personalized medicine 2011-2021	54
Table 13-12: Molecular diagnostic markets according to geographical areas 2011-2021.....	54
Table 13-13: Molecular diagnostic markets according to home-brew and approved tests.....	56
Table 13-14: Marketing strategies for molecular diagnostics.....	60
Table 13-15: Acquisitions of molecular diagnostic companies	61
Table 13-16: Advantages of the integration of diagnostics with therapeutics	69
Table 14-1: Top ten players in molecular diagnostics.....	76
Table 14-2: Collaborations of companies in molecular diagnostics	462

Figures

Figure 13-1: Unmet needs in applications of molecular diagnostics	55
Figure 13-2: Proportion of various areas in molecular diagnostic collaborations	64